Calliditas Therapeutics (“Calliditas”) today hosts a Capital Markets Day in Stockholm, moderated by Lars Frick from Börsveckan.
The Capital Markets Day takes place at GT 30, Grev Turegatan 30 in Stockholm. The program will start at 1:00 pm CET, with registration from 12:30 pm CET.
The presentations will be webcasted live at: https://tv.streamfabriken.com/calliditas-therapeutics-cmd-2019 .
The agenda for the day:
13:00-13:20 Introduction, Renée Aguiar-Lucander, CEO
13:20-13.50 IgA nephropathy – An unmet medical need, Professor Jonathan Barratt, the Department of Infection, Immunity & Inflammation, University of Leicester
13:50-14:20 Nefecon Phase 2b study results and Phase 3 development program overview, Jens Kristensen, CMO
14:20-14:30 Regulatory overview and the route to registration, Frank Bringstrup, VP Regulatory
15:20-15:50 US Market potential and commercial strategy for Nefecon, Andrew Udell, Vice President North America Commercial
15:50-16:05 China market – Opportunities for Nefecon, Renée Aguiar-Lucander, CEO
16:30-17:00 Pipeline: orphan liver indications – AIH/PBC, Current research landscape in AILD (focus on PBC and AIH), Dr. Dimitar Tonev, MD
17:00-17:15 Our long-term vision and closing remarks, Renée Aguiar-Lucander, CEO
The information was released for public disclosure, through the agency of the contact person set out below, on November 4, 2019, at 8.00 CET.
For further information, please contact:
Mikael Widell, Head of Communications
Telephone: +46 703 11 99 60
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US. The company is listed on Nasdaq Stockholm (tícker: CALTX). Visit www.calliditas.com for further information.